Acute Kidney Injury (AKI) Epidemiology
Acute Kidney Injury (AKI) Insights and Trends
- According to DelveInsight’s analysis, the total incident cases of AKI patients were ~ 23,076,000 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
- AKI incidence was similar between sexes (young: males 24.1% vs females 19.3%; older: 43.4% vs 42.2%), but females showed greater severity (higher AKI stages) and longer intubation times.
- The condition can occur at any age but is particularly common in elderly individuals, particularly those with multiple underlying health conditions.
- The stage-specific cases of AKI include Stage I, Stage II, and, Stage III. Out of which maximum cases were reported in stage I AKI followed by stage II and Stage III.
- The burden is expected to increase over the next decade due to an aging population and rising prevalence of chronic conditions like diabetes, hypertension, and cardiovascular disease. These trends underscore the urgent need for effective acute kidney failure treatments to address the growing disease burden.
Acute Kidney Injury (AKI) Epidemiology Forecast
- 2025 Incident Cases of AKI: ~23,076,000
- AKI Growth Rate (2026–2036): 1.42% CAGR
DelveInsight's ‘Acute Kidney Injury (AKI) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the AKI, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period |
2022–2036 |
|
Historical Year |
2022–2025 |
|
Forecast Period |
2026–2036 |
|
Base Year |
2026 |
|
Geographies Covered |
|
|
AKI Epidemiology CAGR (Study period/Forecast period) |
1.42% (2026-2036) |
|
AKI Epidemiology Segmentation Analysis |
Patient Burden Assesment
|
Acute Kidney Injury (AKI) Understanding and Diagnosis Algorithm
AKI Overview
AKI is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by Blood Urea Nitrogen (BUN) and Serum Creatinine (sCr) levels over hours to weeks. Signs and symptoms of AKI include nausea, vomiting, weakness, dizziness, and, pain in the lower back. Some patients are asymptomatic (no noticeable symptoms) and others may have generalized non-specific (not specific to kidneys) symptoms.
AKI Diagnosis
The history and physical examination are important in determining the etiology of AKI. The history can identify nephrotoxic medications or a systemic illness contributing to impaired renal function. The physical examination should focus on evaluating intravascular volume status. Skin rashes may indicate an underlying condition (e.g., systemic lupus erythematosus, atheroembolism/vasculitis) or exposure (e.g., drug rash suggesting acute interstitial necrosis) leading to acute kidney injury. The diagnosis of AKI is traditionally based on a rise in serum creatinine and/or a fall in urine output. The laboratory assessment includes the measurement of serum creatinine level, urinalysis, renal biopsy, urine electrolytes, and others.
Further details are provided in the report.
Acute Kidney Injury (AKI) Epidemiology
Key Findings from AKI Epidemiological Analysis and Forecast
- According to DelveInsight’s estimates, the total number of incident cases of AKI in the 7MM was nearly 23,076,000 cases in 2025 and is projected to increase during the forecasted period.
- The total number of incident cases of AKI in the United States was nearly 8,720,135 in 2025.
- Total mortality-adjusted incident cases of AKI in hospitalized patients in the 7MM accounted for approximately 13 million in 2025.
- Among EU4 and the UK, UK accounted for the highest number of AKI cases, followed by Germany, whereas Spain accounted for the lowest number of cases in 2025.
- The stage-specific cases of AKI include Stage I, Stage II, and Stage III. Out of which, the maximum cases were reported in stage I AKI, followed by stage II and Stage III.
- AKI shows a slight male predominance and is most common in individuals aged ≥80 years. However, cases among people younger than 80 are increasing, likely due to age-related decline in kidney function, higher comorbidities (e.g., Chronic Kidney Disease, Diabetes Mellitus), and increased exposure to nephrotoxic and hemodynamic stressors.
Scope of the Report
- The report covers a segment of an executive summary, a descriptive overview of AKI, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
- AKI patient population forecast
Report Key Strengths
- Epidemiology‑based (epi‑based) bottom‑up forecasting
- 11-year forecast
- Patient burden trends (by geography)
FAQs
- What are the disease risks, burdens, and unmet needs of AKI? What will be the growth opportunities across the 7MM concerning the patient population with AKI?
- What is the historical and forecasted AKI patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
-market-report.png&w=256&q=75)
